1. Home
  2. PLBC vs NGNE Comparison

PLBC vs NGNE Comparison

Compare PLBC & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Plumas Bancorp

PLBC

Plumas Bancorp

HOLD

Current Price

$55.83

Market Cap

363.9M

Sector

Finance

ML Signal

HOLD

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$31.48

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLBC
NGNE
Founded
1980
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
363.9M
327.8M
IPO Year
2002
2014

Fundamental Metrics

Financial Performance
Metric
PLBC
NGNE
Price
$55.83
$31.48
Analyst Decision
Buy
Strong Buy
Analyst Count
3
7
Target Price
$57.67
$63.57
AVG Volume (30 Days)
64.8K
127.6K
Earning Date
04-15-2026
05-08-2026
Dividend Yield
2.60%
N/A
EPS Growth
N/A
0.93
EPS
1.38
N/A
Revenue
N/A
N/A
Revenue This Year
$25.59
N/A
Revenue Next Year
$5.15
N/A
P/E Ratio
$39.72
N/A
Revenue Growth
N/A
N/A
52 Week Low
$39.70
$14.65
52 Week High
$57.51
$37.27

Technical Indicators

Market Signals
Indicator
PLBC
NGNE
Relative Strength Index (RSI) 59.01 65.03
Support Level $50.35 $19.27
Resistance Level N/A $33.00
Average True Range (ATR) 1.41 2.05
MACD 0.03 0.34
Stochastic Oscillator 59.09 91.04

Price Performance

Historical Comparison
PLBC
NGNE

About PLBC Plumas Bancorp

Plumas Bancorp provides banking products and services in Northeastern California and Northwestern Nevada, offering a range of deposit products for commercial and retail customers, including checking, savings, money market accounts, time deposits, retirement accounts, and sweep accounts for businesses and public entities, along with digital banking services such as mobile and internet banking, remote deposit, and electronic funds transfers, as well as other customary banking services. Its loan portfolio comprises commercial real estate, commercial and industrial, consumer, agricultural, residential real estate, and construction and land development loans, and the company generates its revenue from loans and investment securities, with additional income from service fees.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: